Matrixyl vs Liraglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Matrixyl
Matrixyl (Palmitoyl Pentapeptide-4) is a signal peptide that stimulates collagen and extracellular matrix production. It is one of the most well-studied anti-aging peptides with proven efficacy for wrinkle reduction.
Full details →Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →Side-by-Side Comparison
| Aspect | Matrixyl | Liraglutide |
|---|---|---|
| Mechanism | Mimics collagen breakdown fragments, triggering fibroblasts to produce new collagen, elastin, and other matrix components. Essentially tricks skin into repair mode without actual damage. | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. |
| Typical Dosage | Topical: 2-8% concentration in serums and creams. Matrixyl 3000 combines it with Palmitoyl Tetrapeptide-7 for enhanced effects. | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. |
| Administration | Topical application 1-2 times daily. Can be combined with other actives like retinol, vitamin C, and other peptides. | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. |
| Side Effects | Very well-tolerated. Rare mild irritation. Suitable for sensitive skin types. | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. |
| Best For |